REVIEWS
- 期刊名称French Studies
- 作者SHORLEY, C.
- 期第3期
- 印刷ISSN0016-1128
- 电子ISSN1468-2931
- 文件大小61.32KB
- 发表时间1996-07-01
- DOI10.1093/fs/L.3.360
- 页码360-360
MANAGER'S NOTICES. TO SUBSCRIBERS.Stewart, G.D.; Laird, A.; O'Mahony, F.C.; Eory, L.; Lubbock, A.L.R.; Nanda, J.; O'Donnell, M.; Mackay, A.; Mullen, P.; McNeill, S.A.; Riddick, A.C.P.; Peters, J.; Patki, P.; Aitchison, M.; Berney, D.; Bex, A.; Overton, I.M.; Harrison, D.J.; Powles, T. · The Lancet · 1908
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal CancerStewart, G. D.; O'Mahony, F. C.; Laird, A.; Eory, L.; Lubbock, A. L. R.; Mackay, A.; Nanda, J.; O'Donnell, M.; Mullen, P.; McNeill, S. A.; Riddick, A. C. P.; Berney, D.; Bex, A.; Aitchison, M.; Overton, I. M.; Harrison, D. J.; Powles, T. · Clinical Cancer Research · 2015
Cytoreductive nephrectomy in metastatic renal cell carcinoma: Outcomes of patients treated with a multidisciplinary algorithm-driven approachLiu, W.K.; Lam, J.M.; Bex, A.; Powles, T. · European Urology Supplements · 2019
197 The effect of anti-VEGF tyrosine kinase inhibitors on biomarkers and tumour heterogeneity in metastatic clear cell renal cancerStewart, G.D.; Laird, A.; O'Mahony, F.C.; Eory, L.; Lubbock, A.L.R.; Nanda, J.; O'Donnell, M.; Mackay, A.; Mullen, P.; McNeill, S.A.; Riddick, A.C.P.; Peters, J.; Patki, P.; Aitchison, M.; Berney, D.; Bex, A.; Overton, I.M.; Harrison, D.J.; Powles, T. · European Urology Supplements · 2014
The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal CancerSharpe, K.; Stewart, G. D.; Mackay, A.; Van Neste, C.; Rofe, C.; Berney, D.; Kayani, I.; Bex, A.; Wan, E.; O'Mahony, F. C.; O'Donnell, M.; Chowdhury, S.; Doshi, R.; Ho-Yen, C.; Gerlinger, M.; Baker, D.; Smith, N.; Davies, B.; Sahdev, A.; Boleti, E.; De Meyer, T.; Van Criekinge, W.; Beltran, L.; Lu, Y.-J.; Harrison, D. J.; Reynolds, A. R.; Powles, T. · Clinical Cancer Research · 2013
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN projectKramar, A.; Negrier, S.; Sylvester, R.; Joniau, S.; Mulders, P.; Powles, T.; Bex, A.; Bonnetain, F.; Bossi, A.; Bracarda, S.; Bukowski, R.; Catto, J.; Choueiri, T. K.; Crabb, S.; Eisen, T.; El Demery, M.; Fitzpatrick, J.; Flamand, V.; Goebell, P. J.; Gravis, G.; Houédé, N.; Jacqmin, D.; Kaplan, R.; Malavaud, B.; Massard, C.; Melichar, B.; Mourey, L.; Nathan, P.; Pasquier, D.; Porta, C.; Pouessel, D.; Quinn, D.; Ravaud, A.; Rolland, F.; Schmidinger, M.; Tombal, B.; Tosi, D.; Vauleon, E.; Volpe, A.; Wolter, P.; Escudier, B. · Annals of Oncology · 2015
Paratesticular rhabdomyosarcoma in adult patients: 16-year experience at Institut Gustave-Roussy.Kattan, J; Culine, S; Terrier-Lacombe, M J; Theodore, C; Droz, J P · Annals of oncology : official journal of the European Society for Medical Oncology / ESMO · 1993
Combination immunotherapy approachesDrake, C. G. · Annals of Oncology · 2012
Advances in immuno-oncologyEggermont, A.; Finn, O. · Annals of Oncology · 2012
Thanks to referees 2011Annals of Oncology · 2012
OsteosarcomaRitter, J.; Bielack, S. S. · Annals of Oncology · 2010
The role of chemotherapy in cholangiocarcinomaThongprasert, S. · Annals of Oncology · 2005
Spirituality in the cancer trajectoryPuchalski, C. M. · Annals of Oncology · 2012
New insights into pancreatic cancer biologyHidalgo, M. · Annals of Oncology · 2012